The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is the first pooled analysis on coffee and post-surgical flatulence, and while the reduction is real in these studies, the underlying trials were small and unblinded, so the effect may shrink — or vanish — once better research comes in.
This null result undermines the popular belief that black cohosh reliably reduces menopausal hot flashes, but with only three studies total (one positive, two neutral), the picture is far from settled — the overall strength of the evidence is low.
This is one of the first rigorous summaries to pin a specific, moderate-sized drop in diastolic pressure on resveratrol, but because the effect was seen only in people with type 2 diabetes, it's too early to assume the same would happen for someone without that condition.
This is among the first pooled analyses on ashwagandha and cortisol, so the result is promising but far from settled — especially since the underlying trials weren't blinded, which can inflate perceived benefits.
This finding flips the usual narrative that coffee is mostly protective for the heart, but it comes from a tiny pool of just two studies and contradicts the review’s own results for other cardiovascular outcomes, so the picture is now contested rather than settled.
For people undergoing contrast-dye procedures (like CT scans or angiograms), adding NAC to standard hydration meaningfully reduced acute kidney injury — but this is early evidence from a specific clinical population, not a general health recommendation.
This is the first solid meta-analytic evidence tying NAC to progesterone in PCOS, but with only a handful of studies behind it, the finding is intriguing rather than definitive.
This tells us that, so far, the evidence for anthocyanins specifically is weak and inconclusive; don't treat this single small meta-analysis as the final word, but it does pop the bubble of any hype that 'all polyphenols work the same' for weight.
This challenges the blanket assumption that olive oil is always the superior choice for heart health, but the finding is preliminary and based on a single meta-analysis where the olive oil group didn't actually worsen blood pressure on its own — it just didn't lower it as much as the mixed-nut group did.
This is among the first controlled studies linking quercetin to altitude sickness prevention, and while the effect is unusually large, it comes from a small, early-phase trial that needs independent replication before drawing firm conclusions.
This is a large effect from a moderately strong body of evidence (4 of 7 studies show benefit, none show harm), but the small total sample and moderate statistical heterogeneity mean the precise size of the benefit is still uncertain.
This is one of the first randomized trials testing NAC for this condition; the null result suggests it is not effective in this population, but the body of evidence is still too thin to draw a final conclusion.
This is a moderately large effect for a supplement, but the evidence comes from a specific clinical group (type 2 diabetes), so results may not apply to people without the condition. Across 7 studies, most found a benefit, giving moderate confidence in the finding.
This is early evidence from a single meta-analysis; while promising, the unspecified dose and clinical population mean the findings need replication before we can trust them broadly.
This null result contradicts the common assumption that L-DOPA improves mood, but because it comes from a single meta-analysis in stroke rehabilitation — and is among the first studies on this pairing — the picture is far from settled, especially for healthy people or other conditions.
This is the first large, rigorous test of NAC for attention in a clinical population, and the null result directly contradicts the hype from earlier animal studies — but because the trial was done in children with a specific genetic condition (neurofibromatosis type 1), the finding may not apply to healthy adults or other groups.
This is among the first meta-analyses to link selenium levels with colon cancer risk, but the same study failed to find a significant effect on rectal or overall colorectal cancer, so the result is intriguing but far from settled.
This is the first systematic review to look at diet and temporomandibular disorder, but with just one small trial on vitamin D, the evidence is too thin to draw any conclusion — treat this as an early signal, not a settled answer.
This is among the first studies to flag a specific role for tocotrienols in brain structure, but because it's a scoping review of heterogeneous studies, it's a signal, not a conclusion.
This is one of the first comprehensive looks at the question, so the null result challenges the popular idea that vitamin D protects against melanoma, but the limited quality of the underlying studies means we can't rule out a real effect — the picture is now contested, not closed.
This is the first moderately strong evidence that taurine might improve blood sugar control, but it comes entirely from people recovering from COVID-19, and the underlying studies disagreed on how much it helped — so treat it as an early signal, not a settled fact.
This is a promising signal for a specific, high-risk group, but the finding comes from only a handful of studies and needs replication before it changes practice.
This is among the first large-scale analyses to test the link between high iodine and thyroid nodules, and the null result means the picture is still contested — don't treat this as settled evidence either way.
This large, long-term RCT challenges the common assumption that high-dose vitamin D prevents falls, but it's one study — the overall body of evidence on this specific pairing is still thin, so the picture isn't settled.
This is an early finding from a meta-analysis, so the picture is far from settled — but it suggests that while iodine helps correct thyroid function in deficient mothers, it might also trigger a temporary gland enlargement in specific subgroups, leaving a nuance worth watching as more evidence accumulates.
This null result questions a popular assumption, but because it's among the first studies on this specific pairing and relied on genetic proxies rather than supplementation, it does not settle the question – treat it as a cautious first look, not a final answer.
This is the first solid data linking vitamin C to a specific lung complication in premature babies, but with only 538 infants and no neurodevelopmental benefit seen, it's too early to recommend supplementation based on this result alone.
This is among the first indexed reviews on riboflavin for neurological disorders, so the finding is novel but preliminary: the apparent benefit for stroke and perinatal asphyxia rests on small studies and needs replication before it changes practice.
This is the first controlled trial to link whey protein to stronger breathing muscles in the elderly, and the effect was statistically robust — but until other labs confirm it in broader populations, treat it as an intriguing lead, not a settled fact.
This challenges the common belief that calcium supplements alone are enough to ward off low blood calcium after thyroid surgery, but the result is specific to a clinical population and the evidence base is still thin — one review doesn't settle the picture.